FDA

The Association of American Feed Control Officials this week is considering allowing chicken feed producers to include hemp seed as an ingredient, so long as the hemp seed only constitutes a maximum of 20% of the product.

The DEA has reportedly agreed to reschedule cannabis under Schedule III of the Controlled Substances Act, in accordance with the FDA’s recent recommendation. While this development could loosen financial restrictions for brands operating in state markets, advocates have pointed out that it does not resolve the ongoing social injustices surrounding cannabis criminalization, and that it could benefit larger corporate entities that are angling to dominate the market.

FDA Commissioner Robert Califf said during testimony before a House committee this week that there’s “no reason” for the DEA to “delay” its cannabis rescheduling decision.

Fourteen Republican lawmakers have sent a letter to DEA Administrator Anne Milgram, urging the agency to reject the recent Department of Health and Human Services recommendation to reclassify cannabis from Schedule I to Schedule III under federal law.

A coalition of CBD companies has submitted a study to U.S. officials showing that upper intake levels of 70 milligrams of CBD per day are safe for healthy adults and that up to 160 milligrams per day are safe for healthy adults who are not trying to conceive, are pregnant, or lactating.

The U.S. Department of Health and Human Services has recommended that cannabis be moved from a Schedule I to Schedule III substance under federal law.

The U.S. Food and Drug Administration has released its Draft Guidance for the research of psychedelic drugs including substances such as psilocybin, LSD, and MDMA.

Charlotte’s Web Holdings Inc. announced it is partnering with a British American Tobacco subsidiary and AJNA BioSciences to pursue an FDA-approved, full-spectrum hemp extract botanical drug.

The FDA will not regulate CBD products as dietary supplements but the agency said it would “work with Congress” to establish rules for hemp-derived cannabinoid products, which are federally legal but remain unregulated.

The FDA released its proposed final guidance for research related to developing drugs containing cannabis or cannabis-derived compounds.

The FDA posted warning letters to five companies for allegedly selling illegal CBD food and beverage products.

A Florida company has announced clinical trials for the first-ever drug seeking to treat cannabis use disorder.

The National Industrial Hemp Council of America is seeking quick approval from the FDA to include hempseed-based ingredients in animal feed.

The FDA has tapped a former New York and Rhode Island cannabis regulator as its first senior policy advisor on cannabis.

The Idaho State Department of Agriculture will be banning hemp and hemp-derived products in pet food, animal feed, and supplements starting November 1. 

The U.S. House Agriculture Committee held a hearing last week to discuss the state of the hemp industry and how the government can continue to support the crop.

Filament Health has begun its Phase 1 study investigating naturally-derived psilocin and psilocybin, the first such study ever approved by the FDA.

Oregon is banning the sale of synthetic cannabinoids by retailers not licensed by the OLCC due to concerns over chemicals used during the products’ creation.

Kansas Gov. Laura Kelly (D) has signed a bill allowing state residents to consume FDA-approved drugs derived from cannabis.

Two companies have accused the DEA of delaying the application process for bulk cannabis manufacturing in the production of cannabinoid-based pharmaceuticals.

The U.S. Trademark Trial and Appeal Board declined to register a hemp CBD company’s trademark, citing the federal prohibition of CBD and saying the product meets the definition of a drug but has not been approved by the FDA.

A recent poll found that less than half of U.S. parents know much about the use of CBD products with regard to children and most have never tried CBD themselves.

An Idaho bill proposes legalizing nabiximols, a cannabis-derived pain relief spray for patients with multiple sclerosis and other neurological disorders. Cannabis remains otherwise prohibited in the state.

The biotech pharma firm ANANDA Scientific Inc. announced it has received FDA approval to study a CBD-based drug as a treatment for opioid-use disorder.